Contact this trialFirst, we need to learn more about you.
MAPK Pathway Inhibitor
Tovorafenib + Pimasertib for Cancer
Recruiting1 awardPhase 1 & 2
Toronto, Ontario
This trial is testing Tovorafenib, a drug that blocks proteins needed for cancer cell growth, in patients aged 12+ with hard-to-treat melanoma or other solid tumors.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.